Even a cursory look at http://www.dbv-technologies.com/en/, the website of French medical research company DBV Technologies, will reveal that there’s some really interesting work going on in the sphere of allergy research.
On top of this, the Paris-based company is looking into ways of treating eosinophilic esophagitis, a chronic immune system disease, which has only been identified relatively recently. The main focus of its activities does however remain the diagnosis and treatment of three very common allergies: cows’ milk protein allergy, peanut allergy and hen’s egg allergy.
The avenue that DBV Technologies has been exploring over the past number of years is an epicutaneous immunotherapy approach called Viaskin. This is a patch placed on the skin, which is coated in a layer of antigens (the substances which trigger allergic responses in the body). Initially sprayed upon the patch in liquid form by the electrospray technology you can see below, these antigens dry out on the patch’s titanium backing. It’s only upon contact with the skin and the body’s natural warmth that they resolubilize in the patient’s perspiration and are able to penetrate the epidermis to deliver their load.